

Remarks

In response to the Official Action mailed June 6, 2007, Applicants hereby elect with traverse, Group I, Claims 1-2 drawn to a method of making a peptide. Claims 3-6 are withdrawn as being drawn to a non-elected subject matter.

Further, the Official Action has required the Applicants to elect a single species for prosecution on the merits. With respect to species election a), Applicants elect the compound of formula I wherein R1 is $-\text{CH}_2\text{CH}_2\text{NH}_2$ and wherein R2 is $-\text{C}_6\text{H}_5-\text{O}-\text{CH}_2-\text{C}_6\text{H}_5$. This elected species is also disclosed on page 5, line 7 of the specification, namely the compound cyclo [{{(4-NH₂-C₂H₄-NH-CO-O)-Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe}].

With respect to species election b), for the linear somastatin analog which is to be cyclized, Applicants elect the compound of Formula II in claim 1.


Claims 1 and 2 are readable on the designated species.

The above designations are made with the understanding that this application is not limited to the designated species, and with the understanding that upon allowance of a claim generic to the designated species, applicants will be entitled to examination in this application of additional species.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: August 10, 2007